Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva is supported by lanifibranor’s differentiated pan-PPAR mechanism, which targets metabolic dysfunction, inflammation, and fibrotic remodeling in MASH while also offering glycemic benefit in a disease where diabetes is common. Its Phase 2b data were already strong, with 18% placebo-adjusted fibrosis improvement and 26% response in F2/F3 patients on the stringent composite endpoint, and the longer 72-week Phase 3 design should allow responses to deepen. The setup is further strengthened by conservative powering, favorable Phase 3 baseline enrichment in F3 and T2D patients, manageable weight gain/edema, and cash runway through 2Q 2027 with upside from potential financing support after positive data.

Inventiva is weighed down by lanifibranor’s unresolved tolerability profile, with Phase 2b showing about 33% of patients gaining more than 5% weight, edema signals, and roughly 4% discontinuation due to adverse events, all of which could worsen in a longer Phase 3 setting. The investment case also depends on a highly uncertain Phase 3 outcome in a crowded MASH market where competitors may offer better efficacy or safety, while concerns about liver enzyme elevations, serious adverse events, and cardiac effects remain unresolved. As a clinical-stage company with an ongoing need to raise capital and a fully diluted market cap of about $1.8–$1.9B despite no approved product, Inventiva faces material dilution and commercialization risk if lanifibranor fails to deliver clean efficacy and safety data.